A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Etrumadenant (AB928)
RADIATION: Radiation therapy
DRUG: FOLFOX regimen
DRUG: Zimberelimab (AB122)

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]